Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2024.04.007

Abstract

Abstract: Objective To explore the clinical significance of steroid hormones in the diagnosis of polycystic ovary syndrome (PCOS) and to improve the detection rate of hyperandrogenemia (HA) through liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Methods The study included 100 PCOS patients with clinical HA and 100 controls were recruited at the Department of Gynecology and Endocrinology of the Beijing Obstetrics and Gynecology Hospital, Capital Medical University from January to December 2023. The receiver operating characteristic (ROC) curve and area under curve (AUC) were used to evaluate the diagnostic efficacy of various androgen levels including total testosterone (TT), free testosterone (FT), bioavailable testosterone (BIO-T), androstenedione (A2), 17-Hydroxyprogesterone, dihydrotestosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, sex hormone-binding globulin for PCOS . The diagnostic value of chemiluminescence immunoassay (CLIA) and LC-MS/MS in detecting serum TT levels was compared with each other. The HA detection rate screened by LC-MS/MS and CLIA method was also compared. Results Compared to the control group, patients with PCOS had a higher TT (P<0.05), luteal hormone (LH, P<0.05), LH/［follicle stimulating hormone, (FSH)］ (P<0.05), anti-Müllerian hormone (P<0.05), fasting insulin (P<0.05) and homeostasis models assessment-insulin resistance index (P<0.05) measured by CLIA. The FT showed the highest diagnostic value with the AUC 86.4%（P<0.05, 95%CI: 0.815-0.912）, followed by TT with AUC 84.4% (P<0.05, 95%CI: 0.812-0.909), BIO-T with AUC 82.2% (P<0.05, 95%CI: 0.792-0.896) and A2 with AUC 84.2% (P<0.05, 95%CI: 0.790-0.895) in women with PCOS measured by LC-MS/MS. The TT detection by LC-MS/MS had the higher diagnostic sensitivity for PCOS than that by CLIA (AUC was 0.891 to 0.841). The HA detection rate by LC-MS/MS was significantly higher than that by CLIA in patients with PCOS (P<0.05). Conclusions LC-MS/MS is more sensitive and accurate than CLIA in the detection of various androgen indicators. The diagnosis value of FT is most effective for the diagnosis and early screening for HA of PCOS with the clinical manifestations of high androgen, which make it more suitable for clinical application .

Key words: polycystic ovary syndrome, hyperandrogenemia, liquid chromatography-tandem mass spectrometry, free testosterone, chemiluminescence immunoassay

CLC Number:

R711

Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Ma Jun, Jin Jing. Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome[J]. Journal of Capital Medical University, 2024, 45(4): 602-608.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/602

References

［1］马雪莲, 陆月红, 严李萍, 等. 质谱法与雄激素多指标联合检测在多囊卵巢综合征诊断中的应用［J］. 中国卫生检验杂志, 2022, 32(18): 2237-2241.
［2］多囊卵巢综合征雄激素质谱检测共识专家组, 中国人体健康科技促进会生育力保护与保存专业委员会. 多囊卵巢综合征雄激素质谱检测专家共识［J］. 检验医学, 2023, 38(3): 203-208.
［3］ Teede H J, Misso M L, Costello M F, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome［J］. Fertil Steril, 2018, 110(3): 364-379.
［4］ Joham A E, Norman R J, Stener V E. Polycystic ovary syndrome［J］. Lancet Diabetes Endocrinol, 2022, 10(9): 668-680.
［5］ Alesi S, Forslund M, Melin J, et al. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials［J］. EClinicalMedicine, 2023, 63: 102162.
［6］ Hernández-Jiménez J L, Barrera D, Espinoza-Simón E, et al. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance［J］. Gynecol Endocrinol, 2022, 38(1): 2-9.
［7］ Xu S J, Liu Y, Xue K, et al. Diagnostic value of total testosterone and free androgen index measured by LC-MS/MS for PCOS and insulin resistance［J］. J Clin Lab Anal, 2022, 36(11): e24739.
［8］ Agrawal S, Bisen A C, Sanap S N, et al. LC-MS/MS based quantification of steroidal biomarkers in polycystic ovary syndrome induced rats［J］. J Pharm Biomed Anal, 2023, 234: 115484.
［9］ Ge J J, Yang N, Zhang X L, et al. Steroid hormone profiling in hyperandrogenism and non-hyperandrogenism women with polycystic ovary syndrome［J］. Reprod Sci， 2022, 29(12): 3449-3458.
［10］ Yang Y B, Ding M, Di N, et al. Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-based on liquid chromatography with tandem mass spectrometry measurements［J］. J Clin Lab Anal, 2019, 33(3): e22699.
［11］ Teede H J, Tay C T, Laven J J E, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome［J］. J Clin Endocrinol Metab,2023, 108(10):2447-2469.
［12］翟凤英, 张李伟, 王春荣,等. 国际生命科学学会中国肥胖问题工作组推荐体重指数分类标准的血脂谱验证［J］. 中华流行病学杂志, 2004, 25(2): 117-119.
［13］ Xiao H, Yin T L, Diao L H, et al. Association between immunity and different clinical symptoms in patients with polycystic ovary syndrome［J］. Am J Reprod Immunol, 2023, 90(4): e13780.
［14］ Aburto-Hernández C, Barrera D, Ortiz-Hernández R, et al. Impaired carbohydrate metabolism and excess of lipid accumulation in offspring of hyperandrogenic mice［J］. Metabolites, 2022, 12(12): 1182.
［15］赵越, 阮祥燕, 崔亚美, 等. 不同亚型的多囊卵巢综合征患者临床及实验室指标特征的研究［J］. 首都医科大学学报, 2015, 36(4): 567-572.
［16］赵越, 阮祥燕, 李扬璐, 等. 来曲唑联合高纯度尿促性素治疗克罗米芬耐药的多囊卵巢综合征不孕患者的临床研究［J］. 首都医科大学学报, 2016, 37(4): 431-436.
［17］ Ganie M A, Rashid A, Baba M S, et al. Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): evidences from a single centre data set［J］. Clin Endocrinol (Oxf), 2023, 99(6): 566-578.
［18］ Ezeh U, Ezeh C, Pisarska M D, et al. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism［J］. Fertil Steril, 2021, 115(6): 1557-1568.
［19］ López-Alarcón M, Vital-Reyes V S, Almeida-Gutiérrez E, et al. Obesity and hyperandrogenemia in polycystic ovary syndrome: clinical implications［J］. J Pers Med, 2023, 13(9): 1319.
［20］ Qu X Q, Donnelly R. Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome［J］. Int J Mol Sci, 2020, 21(21): 8191.
［21］ Xing C, Zhang J Q, Zhao H, et al. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment［J］. Int J Womens Health, 2022, 14: 91-105.
［22］ Yifu P. Evidence for causal effects of polycystic ovary syndrome on oxidativestress: a two-sample mendelian randomisation study［J］. BMC Med Genomics, 2023, 16(1): 141.

[1]	Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 623-628.
[2]	Zhang Mingzhen, Ruan Xiangyan, Min Min, Alfred O. Mueck. Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 544-549.
[3]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Wang Juan, Cheng Jiaojiao. Investigation on awareness of the benefits from lifestyle intervention in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 555-560.